Severity assessment of single-dose Oxford-AstraZeneca vaccinated individuals infected with severe acute respiratory syndrome coronavirus 2 in Southeast Bangladesh

  1. Eaftekhar Ahmed Rana
  2. Pronesh Dutta
  3. Md. Sirazul Islam
  4. Tanvir Ahmad Nizami
  5. Tridip Das
  6. Sharmin Chowdhury
  7. Goutam Buddha Das

Reviewed by

Read the full article See related articles

Listed in

Log in to save this article

Abstract

Background and Aim: A vaccine program for coronavirus illness (coronavirus disease [COVID-19]) is currently underway in numerous regions of the world, including Bangladesh, but no health data on those who have been vaccinated are available at this time. The study aimed to investigate the health condition of people who had received their first dose of the Oxford- AstraZeneca vaccine and were infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Materials and Methods: To detect SARS-CoV-2, a standard virological approach, real-time reverse transcriptase-quantitative polymerase chain reaction (RT-qPCR), was used. Several health indicators from vaccinated patients were collected using pre-structured questionnaires during the infection phase. Results: A total of 6146 suspicious samples were analyzed, and 1752 were found to be positive for SARS-CoV-2, with 200 people receiving the first dose of the COVID-19 vaccine. One hundred and sixty-five (82.5%) were not hospitalized among the vaccinated people, and 177 (88.5%) did not have any respiratory problems. Only 8% of patients required further oxygen support, and 199 (99.5%) did not require intensive care unit intervention. Overall, oxygen saturation was recorded at around 96.8% and respiratory difficulties did not extend more than 5 days during the infection period. Among the vaccinated COVID-19-positive people, 113 (56.5%) and 111 (55.5%) had typical physiological taste and smell. Surprisingly, 129 (64.5%) people had diverse comorbidities, with high blood pressure (27.9%) and diabetes (32 [24.8%]) being the most common. The major conclusion of the current study was that 199 (99.5%) of vaccinated patients survived in good health and tested negative for RT-qPCR. Conclusion: According to the findings of this study, administering the first dose of the Oxford-AstraZeneca vaccine considerably reduces health risks during the COVID-19 infection period.

Article activity feed

  1. Version published to 10.14202/ijoh.2021.220-226
  2. ScreenIT

    SciScore for 10.1101/2021.05.10.21256529: (What is this?)

    Please note, not all rigor criteria are appropriate for all manuscripts.

    Table 1: Rigor

    EthicsField Sample Permit: Individual samples were collected in separate collection tubes containing viral transport media (VTM) maintaining the WHO guidelines (WHO, 2020).
    Sex as a biological variablenot detected.
    Randomizationnot detected.
    Blindingnot detected.
    Power Analysisnot detected.

    Table 2: Resources

    Software and Algorithms
    SentencesResources
    All data was sorted and coded in Microsoft Excel 2016® excel sheet for further summary and analysis.
    Microsoft Excel
    suggested: (Microsoft Excel, RRID:SCR_016137)

    Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).

    Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

    Results from TrialIdentifier: No clinical trial numbers were referenced.

    Results from Barzooka: We did not find any issues relating to the usage of bar graphs.

    Results from JetFighter: We did not find any issues relating to colormaps.

    Results from rtransparent:
    • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
    • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
    • No protocol registration statement was detected.

    Results from scite Reference Check: We found no unreliable references.

    About SciScore

    SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

  3. Version published to 10.1101/2021.05.10.21256529v1 on medRxiv